PRODUCT DETAILS VIEW ALL PRODUCTS

Clariwin Tablets (Clarithromycin)

  • Clarithromycin 250/500mg Tablets
  • Treatment of mild to moderately severe infections like acute exacerbation of chronic bronchitis community acquired pneumonia including infections due to chlamydia, mycoplasma spegiocella acute streptococcal pharyngitis and skin and soft tissue infections
  • Clarithromycin exerts its antibacterial action by binding to the 50S ribosomal subunit of susceptible bacteria resulting in inhibition of protein synthesis
  • Usual adult dose is 250 mg or 500 mg every 12 hours for 7–14 days.
  • Clarithromycin is contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibiotics, history of cholestatic jaundice/hepatic dysfunction with use of clarithromycin and in patients who are being administered with colchicine.
  • Clarithromycin has been associated with prolongation of the QT interval and infrequent cases of arrhythmia. Clarithromycin should be avoided in patients with ongoing pro-arrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia.
  • Clarithromycin should be used in pregnancy only if clearly needed. Caution should be exercised when clarithromycin is administered to nursing women.Clariwin tablets are not recommended for use in paediatric patients below 12 years of age.
  • Co-administration of Clariwin can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy.Concomitant administration of Clariwin with cisapride and pimozide is contraindicated due to risk of cardiac arrhythmias. Administering Clariwin with HMG CoA reductase inhibitors increases the risk of myopathy, including rhabdomyolysis.
  • The most frequently reported events in adults taking CLARIWIN tablets (clarithromycin tablets) arediarrhoea, nausea, abnormal taste, dyspepsia, abdominal pain/discomfort, and headache.
  • Anti-Bacterials